Fig. 4From: Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center studyBootstrap distribution of cost effectiveness of tocilizumab versus ADM and ETC for CRP level reductionBack to article page